Table 3.
Lipoic acid pharmacokinetic parameters after a 1200 mg oral dose (mean ± SD):
| PK parameters | Formulation A N = 7* |
Formulation B N = 8 |
Formulation C N = 8 |
|---|---|---|---|
| Half-life (min) | 81.2 ± 97.1 | 40.1 ± 17.1 | 35.7 ± 18.2 |
| Tmax (min) | 94.3 ± 50.3 | 71.3 ± 47.9 | 78.8 ± 27.5 |
| Cmax (μg/mL)a | 3.81 ± 2.66 | 9.98 ± 4.53 | 10.28 ± 3.82 |
| Clast (μg/mL) | 0.21 ± 0.24 | 0.11 ± 0.05 | 0.30 ± 0.53 |
| AUC0-last (μg* min/mL)b | 392 ± 290 | 739 ± 308 | 821 ± 327 |
| AUC0-infinity (μg* min/mL) | 443 ± 283 | 745± 308 | 848± 360 |
| Volume of Distribution (mL)c | 377083.7 ± 359686.8 | 107316.1 ± 58474.8 | 85093.2 ± 57905.6 |
| Oral Clearance (mL/min) | 3849.9 ± 2800.6 | 1860.5 ± 740.1 | 1804.9 ± 1207.5 |
*
Number of subjects in each group (N)
a
Formulation A vs. Formulation B P = 0.013; Formulation A vs. Formulation C P = 0.010
b
Formulation A vs. Formulation C P = 0.037
c
Formulation A vs. Formulation B P = 0.046; Formulation A vs. Formulation C P = 0.030